

PATIENT INFORMATION GUIDE



PRE-EXPOSURE PROPHYLAXIS AGAINST COVID-19

EVUSHELD is a prescription medicine used to help prevent adults and adolescents (aged 12 years and older weighing at least 40 kg), who have not been recently in contact with someone who has COVID-19, from getting COVID-19 illness when they:¹

- have an illness or take medicines making them unlikely to respond to or be protected by vaccination against COVID-19
- or are not recommended to have a vaccine due to a history of severe allergies to a COVID-19 vaccine or its components.

EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Ask your doctor if EVUSHELD is right for you. EVUSHELD has risks and benefits, use strictly as directed. If symptoms continue or you have side effects, see your doctor, pharmacist or health professional. EVUSHELD is a temporarily funded medicine for the prevention of COVID-19. A doctor's fee may apply.

This brochure is intended for patients who have been prescribed EVUSHELD. It does not replace the Consumer Medicine Information (CMI), which should be provided to you when you receive treatment. If you have any questions about your treatment, talk to your healthcare team or refer to the full CMI.¹



BEFORE YOU RECEIVE EVUSHELD¹

Check with your healthcare professional if you:



- have low numbers of blood platelets (which help blood clotting)



- have had a heart attack or stroke, have other heart problems, or are at high-risk of cardiac (heart) events



- have a bleeding disorder or are taking a blood-thinning medicine (to prevent blood clots)



- are taking, have recently taken or might take any medicines for any other condition



- have any allergies



- are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby

If you have received a COVID-19 vaccine, tell your healthcare professional prior to using EVUSHELD. It is possible that EVUSHELD may reduce your body's immune response to a COVID-19 vaccine.



EVUSHELD SHOULD NOT BE GIVEN TO YOU IF:¹



- ✘ you are allergic to any of the ingredients in this medicine. Always check the ingredients to make sure you can use this medicine



- ✘ you are under 12 years of age or weigh less than 40 kg

You should also speak to your healthcare professional if you would like further information or if you have any concerns or questions about receiving EVUSHELD.



WHAT SHOULD I KNOW WHILE I AM BEING GIVEN EVUSHELD?¹



Tell your healthcare professional straight away if you notice any signs of serious allergic reaction, such as:

- ? difficulty breathing or swallowing
- ? swelling of the face, lips, tongue or throat
- ? severe itching of the skin, with a red rash or hives

What if I have a side effect?

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. You can let your doctor know about any side effects you may experience and the doctor can report them via <https://nzphvc.otago.ac.nz/reporting/>.

Side effects (adverse events) also include special situations such as pregnancy, dose reduction, discontinuation due to a side effect, or a product quality complaint.

All medicines can have side effects. If you do experience any side effects with EVUSHELD, most of them are minor and temporary. However, some side effects may need medical attention.¹



POSSIBLE SIDE EFFECTS¹

Please consult the full Consumer Medicine Information (CMI) for more details on side effects.

Less serious side effects

Speak to your healthcare professional if you have any of these side effects and they worry you.

Skin → Pain, bruising of the skin, soreness, or swelling at the injection site

Serious side effects

Call your healthcare professional straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Allergies → Allergic reactions may be serious and occur during or following administration of monoclonal antibodies such as those in EVUSHELD.

Tell your healthcare professional straight away if you notice any signs of serious allergic reaction, such as:

Fever, chills, nausea, headache, shortness of breath, low or high blood pressure, rapid or slow heart rate, chest discomfort or pain, weakness, confusion, feeling tired, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, dizziness and sweating

Cardiac (heart) and blood clot events → Serious cardiac and blood clot adverse events have happened, but were not common in the clinical trial studying pre-exposure prophylaxis for the prevention of COVID-19. It is not known if these cardiac and blood clot events are related to EVUSHELD or underlying medical conditions. Symptoms of cardiac events include:

Pain, pressure, or discomfort in the chest, arms, neck, back, stomach, legs or jaw, abdominal pain, shortness of breath, faster than normal heart beat, feeling tired or weak (fatigue), feeling sick (nausea), swelling in your ankles or lower legs, coughing up blood, difficulties speaking or confusion, loss of movement or weakness on one side of the body or face, severe headache



EVUSHELD contains the active ingredients tixagevimab and cilgavimab, types of protein called 'monoclonal antibodies'. They work specifically against SARS-CoV-2 infection, and can help prevent you from getting COVID-19 illness.¹



THINGS YOU SHOULD KNOW ABOUT EVUSHELD¹



It is given to you by a healthcare professional



It is given as two intramuscular injections, usually one into each of your buttocks



It is a combination of two monoclonal antibodies



You will receive two injections one after the other

The recommended dose for prevention of COVID-19 is 300 mg given as two injections:



150 mg of tixagevimab



150 mg of cilgavimab



Reference: 1. EVUSHELD (tixagevimab and cilgavimab) Consumer Medicine Information.

EVUSHELD™ is a registered trademark of the AstraZeneca group of companies. AstraZeneca Limited, PO Box 87453, Meadowbank, Auckland 1742. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone (09) 306 5650 or via <https://contactazmedical.astrazeneca.com> or email Medical Information enquiries to medinfo.nz@astrazeneca.com.

NZ-1625. TAPS MR8536. EVUS0109/EMBC. Date of preparation: September 2022.